List of Regeneron Pharmaceuticals patents

Patents where

Current Assignee

Name

Regeneron Pharmaceuticals

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11369896 Methods for quantitating individual antibodies from a mixture	Patent 11369896 was granted and assigned to Regeneron Pharmaceuticals on June, 2022 by the United States Patent and Trademark Office.	Regeneron Pharmaceuticals	Regeneron Pharmaceuticals	United States Patent and Trademark Office	11369896	June 28, 2022
‌ US Patent 11571636 Methods for quantitating individual antibodies from a mixture		Regeneron Pharmaceuticals	Regeneron Pharmaceuticals	United States Patent and Trademark Office	11571636	February 7, 2023
‌ US Patent 11485793 Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof	Patent 11485793 was granted and assigned to Regeneron Pharmaceuticals on November, 2022 by the United States Patent and Trademark Office.	Regeneron Pharmaceuticals	Regeneron Pharmaceuticals	United States Patent and Trademark Office	11485793	November 1, 2022
‌ US Patent 10179819 Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof	Patent 10179819 was granted and assigned to Regeneron Pharmaceuticals on January, 2019 by the United States Patent and Trademark Office.	Regeneron Pharmaceuticals	Regeneron Pharmaceuticals	United States Patent and Trademark Office	10179819	January 15, 2019
‌ US Patent 11547801 Auto-injector	Patent 11547801 was granted and assigned to Regeneron Pharmaceuticals on January, 2023 by the United States Patent and Trademark Office.	Regeneron Pharmaceuticals	Regeneron Pharmaceuticals	United States Patent and Trademark Office	11547801	January 10, 2023
‌ US Patent 11633501 Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof	Patent 11633501 was granted and assigned to Regeneron Pharmaceuticals on April, 2023 by the United States Patent and Trademark Office.	Regeneron Pharmaceuticals	Regeneron Pharmaceuticals	United States Patent and Trademark Office	11633501	April 25, 2023
‌ US Patent 10893666 Production of fertile XY female animals by silencing of genes on the Y chromosome	Patent 10893666 was granted and assigned to Regeneron Pharmaceuticals on January, 2021 by the United States Patent and Trademark Office.	Regeneron Pharmaceuticals	Regeneron Pharmaceuticals	United States Patent and Trademark Office	10893666	January 19, 2021
‌ US Patent 9657102 Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof	Patent 9657102 was granted and assigned to Regeneron Pharmaceuticals on May, 2017 by the United States Patent and Trademark Office.	Regeneron Pharmaceuticals	Regeneron Pharmaceuticals	United States Patent and Trademark Office	9657102	May 23, 2017
‌ US Patent 11578135 Multispecific antigen-binding molecules binding to a target and an internalizing effector protein that is CD63 and uses thereof	Patent 11578135 was granted and assigned to Regeneron Pharmaceuticals on February, 2023 by the United States Patent and Trademark Office.	Regeneron Pharmaceuticals	Regeneron Pharmaceuticals	United States Patent and Trademark Office	11578135	February 14, 2023
‌ US Patent 11047863 Methods for de novo protein sequencing	Patent 11047863 was granted and assigned to Regeneron Pharmaceuticals on June, 2021 by the United States Patent and Trademark Office.	Regeneron Pharmaceuticals	Regeneron Pharmaceuticals	United States Patent and Trademark Office	11047863	June 29, 2021
‌ US Patent 11535675 Antigen-binding proteins that antagonize leptin receptor		Regeneron Pharmaceuticals	Regeneron Pharmaceuticals	United States Patent and Trademark Office	11535675	December 27, 2022
‌ US Patent 9565841 Humanized IL-4 and IL-4Rα animals	Patent 9565841 was granted and assigned to Regeneron Pharmaceuticals on February, 2017 by the United States Patent and Trademark Office.	Regeneron Pharmaceuticals	Regeneron Pharmaceuticals	United States Patent and Trademark Office	9565841	February 14, 2017
‌ US Patent 9302015 Anti-PRLR antibodies and methods for killing PRLR-expressing cells	Patent 9302015 was granted and assigned to Regeneron Pharmaceuticals on April, 2016 by the United States Patent and Trademark Office.	Regeneron Pharmaceuticals	Regeneron Pharmaceuticals	United States Patent and Trademark Office	9302015	April 5, 2016
‌ US Patent 12103960 VEGF traps and mini-traps and methods for treating ocular disorders and cancer	Patent 12103960 was granted and assigned to Regeneron Pharmaceuticals on October, 2024 by the United States Patent and Trademark Office.	Regeneron Pharmaceuticals	Regeneron Pharmaceuticals	United States Patent and Trademark Office	12103960	October 1, 2024
‌ US Patent 11576984 Genetically modified mouse with humanized immunoglobulin heavy chain constant region genes and method of using	Patent 11576984 was granted and assigned to Regeneron Pharmaceuticals on February, 2023 by the United States Patent and Trademark Office.	Regeneron Pharmaceuticals	Regeneron Pharmaceuticals	United States Patent and Trademark Office	11576984	February 14, 2023
‌ US Patent 10143186 Common light chain mouse	Patent 10143186 was granted and assigned to Regeneron Pharmaceuticals on December, 2018 by the United States Patent and Trademark Office.		Regeneron Pharmaceuticals	United States Patent and Trademark Office	10143186	December 4, 2018
‌ US Patent 9540449 Anti-PCSK9 antibodies with pH-dependent binding characteristics	Patent 9540449 was granted and assigned to Regeneron Pharmaceuticals on January, 2017 by the United States Patent and Trademark Office.	Regeneron Pharmaceuticals	Regeneron Pharmaceuticals	United States Patent and Trademark Office	9540449	January 10, 2017
‌ US Patent 10464992 VEGF antagonist formulations suitable for intravitreal administration	Patent 10464992 was granted and assigned to Regeneron Pharmaceuticals on November, 2019 by the United States Patent and Trademark Office.	Regeneron Pharmaceuticals	Regeneron Pharmaceuticals	United States Patent and Trademark Office	10464992	November 5, 2019
‌ US Patent 9987500 Human antibodies to PD-1	Patent 9987500 was granted and assigned to Regeneron Pharmaceuticals on June, 2018 by the United States Patent and Trademark Office.	Regeneron Pharmaceuticals	Regeneron Pharmaceuticals	United States Patent and Trademark Office	9987500	June 5, 2018
‌ US Patent 9743647 Humanized IL-4 and IL-4Ra animals	Patent 9743647 was granted and assigned to Regeneron Pharmaceuticals on August, 2017 by the United States Patent and Trademark Office.	Regeneron Pharmaceuticals	Regeneron Pharmaceuticals	United States Patent and Trademark Office	9743647	August 29, 2017
‌ US Patent 11274342 Systems and methods for sequencing T cell receptors and uses thereof	Patent 11274342 was granted and assigned to Regeneron Pharmaceuticals on March, 2022 by the United States Patent and Trademark Office.	Regeneron Pharmaceuticals	Regeneron Pharmaceuticals	United States Patent and Trademark Office	11274342	March 15, 2022
‌ US Patent 10329582 Genetic modification of rats	Patent 10329582 was granted and assigned to Regeneron Pharmaceuticals on June, 2019 by the United States Patent and Trademark Office.	Regeneron Pharmaceuticals	Regeneron Pharmaceuticals	United States Patent and Trademark Office	10329582	June 25, 2019
‌ US Patent 10385359 Targeted modification of rat genome	Patent 10385359 was granted and assigned to Regeneron Pharmaceuticals on August, 2019 by the United States Patent and Trademark Office.	Regeneron Pharmaceuticals	Regeneron Pharmaceuticals	United States Patent and Trademark Office	10385359	August 20, 2019
‌ US Patent 11352446 Methods of making multispecific antigen-binding molecules	Patent 11352446 was granted and assigned to Regeneron Pharmaceuticals on June, 2022 by the United States Patent and Trademark Office.	Regeneron Pharmaceuticals	Regeneron Pharmaceuticals	United States Patent and Trademark Office	11352446	June 7, 2022
‌ US Patent 10477842 Humanized IL-4 and IL-4Rα animals	Patent 10477842 was granted and assigned to Regeneron Pharmaceuticals on November, 2019 by the United States Patent and Trademark Office.	Regeneron Pharmaceuticals	Regeneron Pharmaceuticals	United States Patent and Trademark Office	10477842	November 19, 2019

...

Results per page:

774 results

0 selected

774 results

0 selected